Measuring human factors in port activities by using simulation

This paper describes the Cagliari University portanier cranes simulator, an idea born with the goal to reduce mistakes of the quay crane operator, whose operations are virtually reproduced by the physical simulation model. The quay crane operator is even more under stress due to the growing number of functionalities of the new generations of portanier cranes and to the fact that the personnel is requested with a deeper and deeper level of specialization to operate in the maritime via container transportation, a sector that is living an exponential growth in the last years. The paper will introduce the main simulator components: shelter installation with a 6 degrees of freedom motion platform, for a higher immersive performance to improve training but also to develop a base and applied research, whose goal is to analyze operator performance, by electro medical devices. By the use of the Cagliari simulator (in training, r&d and technological development) we have the goal to reduce accidents, that are usually due to fatigue

Logistics node simulator as an enabler for supply chain development: innovative portainer simulator as the assessment tool for human factors in port cranes

none8This paper focuses on the development of a new generation of interoperable simulators of micro activities in logistics node; the proposed example focuses on a real-time full-scope virtual simulator of port activities able to simulate the activities of whole port by having ships, cranes, trucks, containers interoperating in a federation. The technologies adopted in terms of architecture and installation were very effective in creating a mobile laboratory open to further extension by online interoperation with other simulators and with biomedical devices for assessing human capabilities within this framework. This approach allows us to face the existing challenges in extending the capabilities of logistics node over their current capabilities limited by technological and human factors.mixedA.;Bruzzone; P.; Fadda; G.; Fancello; M.;Massei; E.; Bocca; A.; Tremori; F.; Tarone; G.;D'Errico.Bruzzone, A.; Fadda, P.; Fancello, G.; Massei, M.; Bocca, E.; Tremori, A.; Tarone, F.; D'Errico., G

Effect of RNS60 in amyotrophic lateral sclerosis: a phase II multicentre, randomized, double-blind, placebo-controlled trial

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with limited treatment options. RNS60 is an immunomodulatory and neuroprotective investigational product that has shown efficacy in animal models of ALS and other neurodegenerative diseases. Its administration has been safe and well-tolerated in ALS subjects in previous early phase trials